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INTRODUCTION
Microscopic polyangiitis (MPA) and granulomatosis with poly-
angiitis (GPA) are classified as antineutrophil cytoplasmic an-
tibody (ANCA)-associated vasculitis (AAV). MPA and GPA 
share the pathological characteristics of small-vessel necrotiz-
ing vasculitis, as described in the 2012 Chapel Hill Consensus 
Conferences Nomenclature of Vasculitis (2012 CHCC defini-
tions).1,2 However, clinical features of MPA and GPA are quite 
different: MPA has a predilection to cause necrotizing glomer-
ulonephritis and pulmonary capillaritis, whereas GPA often 
induces the formation of granuloma at the upper and lower 
respiratory tracts and occasionally causes necrotizing glomer-
ulonephritis.3 
Rituximab, a monoclonal antibody against CD20 of B lym-
phocytes, has been widely used as one of the standard thera-
pies for MPA and GPA. The efficacy of rituximab on MPA and 
GPA as both induction and maintenance therapies has been 
shown in the two large clinical trials.4,5 Moreover, rituximab 
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has also been validated to be effective as a remission mainte-
nance therapy in refractory GPA cases.6 The European League 
Against Rheumatism (EULAR) and the European Renal Asso-
ciation-European Dialysis and Transplant Association (ERA-
EDTA) recognized the therapeutic potential of rituximab as 
effective as that of cyclophosphamide (CYC), suggesting that 
a combination of glucocorticoid with either CYC or rituximab 
be administered to newly diagnosed patients with life-threat-
ening AAV.7
Currently, two types of rituximab are widely used, including 
originator (Mabthera®, Roche) and biosimilar (Truxima®, 
Celltrion). Truxima® is the first rituximab biosimilar, and it 
has been approved for the treatment of medical conditions for 
which Mabthera® was also approved.8 The clinical effects of 
Truxima® were compared with those of Mabthera® via several 
clinical trials, and were proved to be effective and safe in pa-
tients with follicular lymphoma and rheumatoid arthritis.9,10 
However, there was no extensive study to analyse the efficacy of 
Truxima® for MPA and GPA with a considerable number of pa-
tients. Here, we investigated whether Truxima® could prevent 
poor outcomes of MPA and GPA as effectively as Mabthera®. 
MATERIALS AND METHODS
Patients
We retrospectively reviewed the medical records of 139 pa-
tients with MPA and GPA from the Severance Hospital ANCA-
associated VasculitidEs (SHAVE) cohort between October 
2000 and March 2019, at the Division of Rheumatology, De-
partment of Internal Medicine, Yonsei University College of 
Medicine, Severance Hospital, Seoul, Republic of Korea. The 
diagnosis of MPA and GPA was based on the 2007 European 
Medicines Agency algorithm for AAV and polyarteritis nodosa 
(the 2007 EMA algorithm) and the 2012 CHCC definitions.1,2 
All patients had well-documented medical records with 
which we could obtain the information on ANCA positivity, 
clinical data, and comorbidities at diagnosis, as well as out-
comes and medications that were administered during fol-
low-up. This study was approved by the Institutional Review 
Board (IRB) of Severance Hospital (4-2017-0673), which 
waived the need for patients’ written informed consent, as 
this was a retrospective study.
Clinical data and ANCA positivity at diagnosis and 
during follow-up
In regard to variables at diagnosis, age and gender were col-
lected as demographic data. We check the positivity of four 
types of ANCA was, including perinuclear (P)-ANCA, cyto-
plasmic (C)-ANCA, myeloperoxidase (MPO)-ANCA and pro-
teinase 3 (PR3)-ANCA. In patients who tested positive in the 
indirect fluorescence assay, but negative in antigen-specific 
assays, P-ANCA positivity was considered as MPO-ANCA 
positivity and C-ANCA positivity as PR3-ANCA positivity.11 We 
also assessed the comorbidities of MPA and GPA at the time 
prior to the initiation of any immunosuppressive drug, such 
as hypertension, chronic kidney disease (CKD) (stage III–V), 
dyslipidaemia, diabetes mellitus, interstitial pneumonia and 
diffuse alveolar haemorrhage.
With regard to variables during follow-up, all-cause mortal-
ity, relapse, end-stage renal disease (ERSD), cerebrovascular 
accident and acute coronary syndrome were evaluated as 
poor outcomes. The follow-up duration was defined as the 
period between the date of AAV diagnosis and the date of the 
last visit for the survived patients. In cases of the deceased pa-
tients, it was defined as the period between the diagnosis of 
AAV and the time of death. For patients who had any poor 
outcomes, it was defined as the period starting from the diag-
nosis of AAV until the time when each poor outcome ap-
peared. Medications administered during follow-up were also 
examined. 
Rituximab 
Two types of rituximab, Mabthera® and Truxima®, were used; 
and both were considered as rituximab in this study. Based 
on the EULAR recommendation, in real clinical settings, we 
have explained that Mabthera® is rituximab originator and 
Truxima® is rituximab biosimilar. Also, we have evenly recom-
mended two drugs for patients in need of rituximab and en-
couraged patients to choose Mabthera® or Truxima® to date.
Statistical analyses
All statistical analyses were conducted using SPSS software 
(version 23 for Windows; IBM Corp., Armonk, NY, USA). Con-
tinuous variables were expressed as median (interquartile 
range), and categorical variables were expressed as number 
and percentage. Significant differences in categorical vari-
ables between the two groups were analysed using chi-square 
and Fisher’s exact tests. Significant differences in continuous 
variables between the two groups were compared using Mann-
Whitney test. Comparison of cumulative survivals between the 
two groups, based on the administration of rituximab, was ana-
lysed by Kaplan-Meier survival analysis with log-rank test. 
The relative risk (RR) of A for B was analysed using contingen-
cy tables and chi-square test. p-values less than 0.05 were 
considered statistically significant.
RESULTS
Characteristics of 139 patients with MPA and GPA 
The median age at diagnosis was 60.1 years, and 46 patients 
were men (97 MPA patients and 42 GPA patients). At diagno-
sis, ANCA was detected in 120 patients (92.3%) and MPO-AN-
CA (or P-ANCA) was positive in 99 patients (71.2%). The most 
common comorbidity at diagnosis was hypertension (44.6%), 
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followed by CKD (30.2%). During follow-up, the most com-
mon poor outcome was relapse (36.0%), followed by ESRD 
(23.2%). The most commonly administered immunosuppres-
sive drug after glucocorticoid (92.1%) was CYC (48.2%), fol-
lowed by azathioprine (47.5%). Twenty-six patients (18.7%) 
received rituximab (Table 1). 
Comparison of variables between patients receiving 
rituximab and those not receiving rituximab 
We compared various clinical aspects between patients who 
received rituximab and those who did not receive rituximab. 
First, we did not observe any significant differences in demo-
graphic data, and AAV variants were found. All patients receiv-
ing rituximab had ANCA at diagnosis, whereas 84.1% of pa-
tients not receiving rituximab had ANCA at diagnosis 
(p=0.024). For the pre-existing comorbidities at diagnosis, pa-
tients in the rituximab group exhibited higher frequencies of 
having CKD (50.0% vs. 25.7%, p=0.015) and dyslipidaemia 
(46.2% vs. 25.7%, p=0.039) compared to those in the non-ritux-
imab group, but other comorbidities were not different be-
tween the two groups. Furthermore, the two groups had  com-
parable follow-up durations. Patients receiving rituximab 
presented relapse more often than those not receiving ritux-
imab (61.5% vs. 30.1% p=0.003). Azathioprine (65.4% vs. 43.4%, 
p=0.043) and mycophenolate mofetil (34.6% vs. 8.8%, p=0.001) 
had been supplied frequently to patients receiving rituximab, 
compared to those not receiving rituximab (Table 2). 
Comparison of the cumulative survival rates of poor 
outcomes between patients receiving rituximab and 
those not receiving rituximab
Using Kaplan-Meier analysis, we analysed and compared the 
cumulative survival rates of poor outcomes of MPA and GPA 
during the follow-up period between patients receiving ritux-
imab and those not receiving rituximab. Among poor out-
comes during the follow-up period, patients receiving ritux-
imab exhibited a significantly lower cumulative relapse-free 
survival rate compared to those not receiving rituximab 
(p=0.002) (Fig. 1). 
Comparison of the cumulative survival rates of poor 
outcomes between Mabthera® and Truxima®
We compared the clinical effects of rituximab on poor out-
comes of MPA and GPA between Mabthera® and Truxima®. 
There were no significant differences in demographic, ANCA 
positivity and comorbidity data at diagnosis, as well as the fre-
quency of poor outcomes and medications administered dur-
ing follow-up between patients receiving Mabthera® and 
Truxima® (Table 3). Moreover, among poor outcomes, pa-
tients receiving Truxima® exhibited a similar pattern of cumu-
lative survival rates of each poor outcome compared to those 
receiving Mabthera® (Fig. 2). 




Age (yr) 60.1 (19.5)




ANCA positivity at diagnosis
MPO-ANCA (or P-ANCA) 99 (71.2)
PR3-ANCA (or C-ANCA) 25 (18.0)
MPO-ANCA (or P-ANCA) and PR3-ANCA (or C-ANCA) 4 (2.9)
ANCA negative 19 (13.7)
Comorbidities at diagnosis
Hypertension 62 (44.6)
CKD (stage III–V) 42 (30.2)
Dyslipidaemia 41 (29.5)
Diabetes mellitus 39 (28.1)
Interstitial lung disease 34 (24.5)
Diffuse alveolar haemorrhage 7 (5.0)
During follow-up
Poor outcomes during follow-up
Relapse 50 (36.0)
ESRD 32 (23.2)
All-cause mortality 14 (10.1)
CVA 12 (8.6)
ACS 9 (6.5)






Mycophenolate mofetil 19 (13.7)
Tacrolimus 10 (7.2)
MPA, microscopic polyangiitis; GPA, granulomatosis with polyangiitis; ANCA, 
antineutrophil cytoplasmic antibody; MPO, myeloperoxidase; P, perinuclear; 
PR3, proteinase 3; C, cytoplasmic; CKD, chronic kidney disease; ESRD, end-
stage renal disease; CVA, cerebrovascular accident, ACS, acute coronary 
syndrome. 
Values are expressed as median (interquartile range) or n (%). 
DISCUSSION
In this study, we investigated the clinical effects of rituximab 
on poor outcomes of MPA and GPA in Korean patients and 
found that the cumulative relapse-free rate in patients receiv-
ing rituximab was much lower than that in patients not receiv-
ing rituximab during follow-up. We interpret this result to 
mean that rituximab was more frequently administered to pa-
tients experiencing any relapse rather than rituximab having 
insufficient efficacy for preventing relapse. To support our 
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Table 2. Comparison of Variables between MPA or GPA Patients Receiving Rituximab and Those Not Receiving Rituximab
Variables Patients receiving rituximab (n=26) Patients not receiving rituximab (n=113) p value
At diagnosis
Demographic data
Age (yr) 57.3 (13.9) 61.0 (20.4) 0.595
Male gender 10 (38.5) 36 (31.9) 0.519
Variants
MPA 17 (65.4) 80 (70.8) 0.588
GPA 9 (34.6) 33 (29.2)
ANCA positivity at diagnosis
MPO-ANCA (or P-ANCA) 21 (80.8) 78 (69.0) 0.337
PR3-ANCA (or C-ANCA) 6 (23.1) 19 (16.8) 0.453
ANCA double positive 1 (3.8) 3 (2.7) 0.568
ANCA negative 0 (0) 19 (15.9) 0.024
Comorbidities during at diagnosis
Hypertension 16 (61.5) 46 (40.7) 0.054
CKD (stage III–V) 13 (50.0) 29 (25.7) 0.015
Dyslipidaemia 12 (46.2) 29 (25.7) 0.039
Diabetes mellitus 6 (23.1) 33 (29.2) 0.531
Interstitial lung disease 8 (30.8) 26 (23.0) 0.407
Diffuse alveolar haemorrhage 2 (7.7) 5 (4.4) 0.615
During follow-up
Follow-up duration (months) 26.0 (57.7) 34.9 (59.7) 0.691
Poor outcomes
Relapse 16 (61.5) 34 (30.1) 0.003
Follow-up duration for relapse (months) 11.4 (23.3) 19.6 (39.3) 0.227
ESRD 7 (26.9) 25 (22.1) 0.600
Follow-up duration for ESRD (months) 27.1 (49.0) 16.1 (52.9) 0.157
All-cause mortality 3 (11.5) 11 (9.7) 0.726
Follow-up duration for death (months) 26.0 (57.7) 34.9 (59.7) 0.701
CVA 3 (11.5) 9 (8.0) 0.697
Follow-up duration for CVA (months) 22.1 (42.3) 28.1 (58.2) 0.679
ACS 2 (7.7) 7 (6.2) 0.675
Follow-up duration for ACS (months) 26.0 (41.4) 33.8 (60.2) 0.666
Medications administered during follow-up
Glucocorticoid 26 (100) 102 (90.3) 0.218
Cyclophosphamide 17 (65.4) 50 (44.2) 0.052
Azathioprine 17 (65.4) 49 (43.4) 0.043
Methotrexate 2 (7.7) 15 (13.3) 0.522
Mycophenolate mofetil 9 (34.6) 10 (8.8) 0.001
Tacrolimus 2 (7.7) 8 (7.8) 1.000
MPA, microscopic polyangiitis; GPA, granulomatosis with polyangiitis; ANCA, antineutrophil cytoplasmic antibody; MPO, myeloperoxidase; P, perinuclear; PR3, 
proteinase 3; C, cytoplasmic; CKD, chronic kidney disease; ESRD, end-stage renal disease; CVA, cerebrovascular accident, ACS, acute coronary syndrome. 
Values are expressed as median (interquartile range) or n (%).
claim, we compared the frequencies of rituximab use between 
patients with and without relapse, and found that rituximab 
was prescribed more often to patients with relapse than those 
without relapse [16 of 50 patients (32.0%) vs. 10 of 89 patients 
(11.2%), p=0.003]. In addition, we obtained a RR of 3.718 for 
having serious vasculitis status requiring rituximab use in re-
lation to the presence of relapse over the absence of relapse. 
In order to get a more accurate analysis in this context, it is 
preferred to compare the variables before and after the use of 
rituximab. However, since we only had one case of relapse af-
ter rituximab administration, statistical analysis of the preven-
tive potential of rituximab for relapse of MPA and GPA was 
not possible. Nevertheless, we believed that the lack of differ-
ence in other poor outcomes of MPA and GPA, except for re-
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lapse, might be a rebuttal to the fact that rituximab use after 
relapse eventually led to good.
There was another evidence for the positive effect of ritux-
imab on poor outcomes of MPA and GPA. At diagnosis, the 
frequency of CKD (stage III–V) in patients receiving rituximab 
was higher than that in patients not receiving rituximab. In 
other words, this result may reflect that the extent of kidney 
involvement of MPA and GPA was more severe in patients re-
ceiving rituximab compared to the other group. However, the 
two groups exhibited similar cumulative ESRD-free survival 
rates during follow-up. This result was in line with the results 
of previous studies;5,12 therefore, we also assumed that ritux-
imab might have a preventive potential against the progres-
sion to ESRD in Korean patients with MPA and GPA.
Like many European countries, the National Health Insur-
ance Service (NHIS) in Korea provides universal healthcare to 
South Korean patients. However, the coverage of rituximab for 
MPA and GAP patients by NHIS is somewhat different than 
those of European countries. Since January 2013, NHIS in Ko-
rea has provided coverage for rituximab to MPA and GPA pa-
tients under special circumstances, such as the following: cas-
es of MPA or GPA which are refractory to CYC, or cases that 
exhibit serious adverse events caused by CYC. Therefore, in 
Korea, the rituximab-based therapy for MPA and GPA is still 
recognized as a secondary induction therapeutic option after 
the use of CYC. If rituximab could be used as a primary induc-
tion therapeutic option for MPA and GPA treatment, we would 
expect a better prognosis for patients with MPA and GPA. 
Here, we compared the two brands of rituximab: Mabthera® 
and Truxima® with respect to therapeutic effects on the out-
comes of MPA and GPA. The Korean NHIS has offered cover-
age of Mabthera® for treating MPA and GPA since January 
2013, whereas, Truxima® has been covered since February 
2017. For this reason, the therapeutic effects and long-term 
outcomes by Truxima® in patients with MPA and GPA have 
been not well-known compared to those by Mabthera®. In the 
present study, we found that the clinical effects of Truxima® 
on poor outcomes of MPA and GPA were not significantly dif-
ferent from those of Mabthera®. This result suggests that Trux-
ima® is as effective as Mabthera® in the treatment of MPA and 
GPA, without worsening any outcomes.
At diagnosis, the frequency of ANCA positivity in patients 
receiving rituximab was significantly higher compared to 
those not receiving rituximab (Table 2). In addition, during 
follow-up, patients receiving rituximab had experienced re-
lapse more often compared to those not receiving rituximab 
(Fig. 1). Taking these results into consideration, we expected 
that the frequency of relapse in patients with ANCA would be 
meaningfully higher than that in those without ANCA. We in-
vestigated whether ANCA positivity at diagnosis might en-
hance the occurrence of poor outcomes of MPA and GPA dur-
ing follow-up using Kaplan Meier survival analysis with log-
rank test. Among poor outcomes, ANCA positivity at diagnosis 
could predict lower cumulative relapse-free survival rate than 
ANCA negativity does at diagnosis (p=0.049). Moreover, 
among poor outcomes other than relapse, patients with 
Fig. 1. Comparison of cumulative survival rates of poor outcomes based on the administration of rituximab. Among five poor outcomes during the follow-
up period, patients receiving rituximab exhibited a significantly lower cumulative relapse-free survival rate than those compared to receiving rituximab. 
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ANCA at diagnosis exhibited significantly reduced cumulative 
ESRD-free survival rate compared to those without ANCA at 
diagnosis (p=0.020) (Supplementary Fig. 1, only online), simi-
lar to previous studies.13,14 Therefore, we concluded that ANCA 
positivity at diagnosis might be closely associated with re-
lapse, which more often required rituximab use compared to 
ANCA negativity.
In addition, interstitial lung disease and diffuse alveolar 
haemorrhage at diagnosis have been known as important risk 
factors for all-cause mortality during follow-up in patients 
with AAV.15,16 The cumulative survival rates were significantly 
lower in patients with interstitial lung disease and those with 
diffuse alveolar haemorrhage at diagnosis compared to those 
without lung manifestations (p=0.034 and p=0.006, respec-
tively) (Supplementary Fig. 2, only online). 
Our study had several limitations. First, it was designed as a 
monocentric study. For this reason, the number of patients re-
ceiving rituximab was not large enough to represent the cur-
rent clinical situation in Korea regarding MPA and GPA. Also, 
due to the study’s retrospective design, we could not exclude 
the possibility of missing data at diagnosis. In addition, as 
mentioned earlier, there was a difference in follow-up dura-
tions between Mabthera®-based group and Truxima®-based 
group, due to the NHIS coverage policy in Korea. This could 
have caused a problem in comparing the clinical effects be-
tween the two groups. However, we believe that our study may 
Table 3. Comparison of Variables between MPA or GPA Patients Receiving Mabthera® and Those Receiving Truxima®
Variables Patients receiving Mabthera® (n=11) Patients receiving Truxima® (n=15) p value
At diagnosis
Demographic data
Age (yr) 55.0 (15.7) 57.5 (13.5) 0.675
Male gender 3 (27.3) 7 (46.7) 0.315
Variants
MPA 8 (72.7) 9 (60.0) 0.683
GPA 3 (27.3) 6 (40.0) 0.683
ANCA positivity at diagnosis
MPO-ANCA (or P-ANCA) 9 (81.8) 12 (80.0) 1.000
PR3-ANCA (or C-ANCA) 3 (27.3) 3 (20.0) 1.000
ANCA double positive 1 (9.1) 0 (0) 0.423
ANCA negative 0 (0) 0 (0)  N/A
Comorbidities during at diagnosis
Hypertension 6 (54.5) 10 (66.7) 0.530
CKD (stage III–V) 4 (36.4) 9 (60.0) 0.428
Dyslipidaemia 5 (45.5) 7 (46.7) 0.951
Diabetes mellitus 3 (27.3) 3 (20.0) 1.000
Interstitial lung disease 4 (36.4) 4 (26.7) 0.683
Diffuse alveolar haemorrhage 1 (9.1) 1 (6.7) 1.000
During follow-up
Poor outcomes
Relapse 8 (72.7) 8 (53.3) 0.428
ESRD 4 (36.4) 3 (20.0) 0.407
All-cause mortality 2 (18.2) 1 (6.7) 0.556
CVA 2 (18.2) 1 (6.7) 0.556
ACS 2 (18.2) 0 (0) 0.169
Medications administered during follow-up
Glucocorticoid 11 (100) 15 (100)  N/A
Cyclophosphamide 6 (54.5) 11 (73.3) 0.419
Azathioprine 7 (63.6) 10 (66.7) 1.000
Methotrexate 2 (18.2) 0 (0) 0.169
Mycophenolate mofetil 4 (36.4) 5 (33.3) 1.000
Tacrolimus 2 (18.2) 0 (0.0) 0.169
MPA, microscopic polyangiitis; GPA, granulomatosis with polyangiitis; ANCA, antineutrophil cytoplasmic antibody; MPO, myeloperoxidase; P, perinuclear; PR3, 
proteinase 3; C, cytoplasmic; N/A, not applicable; CKD, chronic kidney disease; ESRD, end-stage renal disease; CVA, cerebrovascular accident; ACS, acute coro-
nary syndrome. 
Values are expressed as median (interquartile range) or n (%).
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Fig. 2. Comparison of cumulative survival rates of poor outcomes between rituximab originator (Mabthera®) and biosimilar (Truxima®). Among five poor 
outcomes, patients receiving Truxima® exhibited a similar pattern of cumulative survival rates for each poor outcome compared to those receiving 
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still offer some clinical significance to demonstrate the effect 
of rituximab use on the prognosis of MPA and GPA in Korean 
patients, as the first pilot study conducted in the biggest AAV 
cohort in Korea. Furthermore, this study was the first to com-
pare the effect of Truxima® on poor outcomes of MPA and GPA 
with that of Mabthera®. 
In conclusion, rituximab is an effective therapeutic modali-
ty for treating severe MPA and GPA in Korean patients. Also, 
Truxima® prevents poor outcomes of MPA and GPA as effec-
tively as does Mabthera®.
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